Treat-to-target in systemic lupus erythematosus: where are we today?

Marta Mosca; Dimitrios T Boumpas; Ian N Bruce; Ricard Cervera; Laszlo Czirjak; Thomas Dörner; Frédéric Houssiau; Soren Jacobsen; Matthias Schneider; Josef S Smolen; Alexandre E Voskuyl; Ronald F van Vollenhoven

Treat-to-target in systemic lupus erythematosus: where are we today?

Marta Mosca, Dimitrios T Boumpas, Ian N Bruce, Ricard Cervera, Laszlo Czirjak, Thomas Dörner, Frédéric Houssiau, Soren Jacobsen, Matthias Schneider, Josef S Smolen, Alexandre E Voskuyl, Ronald F van Vollenhoven

Abstract

Multiple clinical trials performed over twenty years in the treatment of rheumatoid arthritis (RA) have clearly demonstrated that patients have better outcomes if their disease activity at each time-point for follow-up includes a pre-specified target. A European SLE expert panel met in Zurich on May 8, 2012 to discuss whether a treat-to-target approach could be applied in the treatment of systemic lupus erythematosus (SLE) (T2T/SLE), define a research agenda, and establish a plan for moving forward. In the present paper, observations raised at the meeting and literature data on potential therapeutic targets are reported. The working group on T2T/SLE will continue work over the coming year.

Original language	English
Journal	Clinical and Experimental Rheumatology
Volume	30
Issue number	4 Suppl 73
Pages (from-to)	S112-5
ISSN	0392-856X
Publication status	Published - 2013

Access to Document

http://www.clinexprheumatol.org/abstract.asp?a=6487

Cite this

Mosca, M., Boumpas, D. T., Bruce, I. N., Cervera, R., Czirjak, L., Dörner, T., Houssiau, F., Jacobsen, S., Schneider, M., Smolen, J. S., Voskuyl, A. E., & van Vollenhoven, R. F. (2013). Treat-to-target in systemic lupus erythematosus: where are we today? Clinical and Experimental Rheumatology, 30(4 Suppl 73), S112-5. http://www.clinexprheumatol.org/abstract.asp?a=6487

@article{66683bd0868c4c24b95f108381007d64,

title = "Treat-to-target in systemic lupus erythematosus: where are we today?",

abstract = "Multiple clinical trials performed over twenty years in the treatment of rheumatoid arthritis (RA) have clearly demonstrated that patients have better outcomes if their disease activity at each time-point for follow-up includes a pre-specified target. A European SLE expert panel met in Zurich on May 8, 2012 to discuss whether a treat-to-target approach could be applied in the treatment of systemic lupus erythematosus (SLE) (T2T/SLE), define a research agenda, and establish a plan for moving forward. In the present paper, observations raised at the meeting and literature data on potential therapeutic targets are reported. The working group on T2T/SLE will continue work over the coming year.",

author = "Marta Mosca and Boumpas, {Dimitrios T} and Bruce, {Ian N} and Ricard Cervera and Laszlo Czirjak and Thomas D{\"o}rner and Fr{\'e}d{\'e}ric Houssiau and Soren Jacobsen and Matthias Schneider and Smolen, {Josef S} and Voskuyl, {Alexandre E} and {van Vollenhoven}, {Ronald F}",

year = "2013",

language = "English",

volume = "30",

pages = "S112--5",

journal = "Clinical and Experimental Rheumatology",

issn = "0392-856X",

publisher = "Pacini Editore SpA",

number = "4 Suppl 73",

}

TY - JOUR

T1 - Treat-to-target in systemic lupus erythematosus

T2 - where are we today?

AU - Mosca, Marta

AU - Boumpas, Dimitrios T

AU - Bruce, Ian N

AU - Cervera, Ricard

AU - Czirjak, Laszlo

AU - Dörner, Thomas

AU - Houssiau, Frédéric

AU - Jacobsen, Soren

AU - Schneider, Matthias

AU - Smolen, Josef S

AU - Voskuyl, Alexandre E

AU - van Vollenhoven, Ronald F

PY - 2013

Y1 - 2013

N2 - Multiple clinical trials performed over twenty years in the treatment of rheumatoid arthritis (RA) have clearly demonstrated that patients have better outcomes if their disease activity at each time-point for follow-up includes a pre-specified target. A European SLE expert panel met in Zurich on May 8, 2012 to discuss whether a treat-to-target approach could be applied in the treatment of systemic lupus erythematosus (SLE) (T2T/SLE), define a research agenda, and establish a plan for moving forward. In the present paper, observations raised at the meeting and literature data on potential therapeutic targets are reported. The working group on T2T/SLE will continue work over the coming year.

AB - Multiple clinical trials performed over twenty years in the treatment of rheumatoid arthritis (RA) have clearly demonstrated that patients have better outcomes if their disease activity at each time-point for follow-up includes a pre-specified target. A European SLE expert panel met in Zurich on May 8, 2012 to discuss whether a treat-to-target approach could be applied in the treatment of systemic lupus erythematosus (SLE) (T2T/SLE), define a research agenda, and establish a plan for moving forward. In the present paper, observations raised at the meeting and literature data on potential therapeutic targets are reported. The working group on T2T/SLE will continue work over the coming year.

M3 - Journal article

SN - 0392-856X

VL - 30

SP - S112-5

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

IS - 4 Suppl 73

ER -

Treat-to-target in systemic lupus erythematosus: where are we today?

Abstract

Access to Document

Fingerprint

Cite this